Date(s) - November 12,2021 - November 14,2021
8:00 am - 1:00 pm
Excellence El Carmen
HOTEL INFO: Please call us to assist with your room reservation
Excellence El Carmen (adult only resort)
Mandatory to stay at this resort if attending seminars
Please fly into Punta Cana International Airport.
Dr. Stan Louie, Pharm D.
University of Southern California
Dr. Stan Louie received his Doctorate in Pharmacy from the University of California in San Francisco. He continued his postgraduate work at Pacific Presbyterian Medical Center in San Francisco where he was a pharmacy resident. In addition to clinical training, he continued his basic science training at the Kuzell Institute, where he served as Associate of Research in Molecular Biology. Following his training at Kuzell, he joined USC where he continued his work on cytokine regulation in relation to tumor and/or viral proliferation at the Kenneth Norris Cancer Research Institute. Presently, he is an Associate Professor at the University of Southern California School of Pharmacy and the Keck School of Medicine, where he is concentrating his work on virally-linked diseases, which include HIV and hepatitis B & C. In addition, he continues his efforts in drug discovery and development for the treatment of specific brain cancers and multiple myeloma.
Friday November 12, 2021
1. Overview the current epidemiology of viral infections and their clinical impact.
2. Identify the mechanism(s) of action of various antiviral and antibacterial agents.
3. Describe the effect of combination therapy and how they can enhance clinical activity.
4. Describe the adverse effect profiles that a patient may expect when receiving some of these agents.
5. Identify possible drug-drug interactions and develop strategies to circumvent these problems.
Saturday November 13, 2021
ACPE # TBA
1. Recognize the mechanism of injury induced by radiation.
2. Determine the window of opportunity for radiation-induced injuries (e.g. GI, hematologic, and cutaneous injuries).
3. Be able to manage the efficacy and adverse effects associated with new mitigation agents.
4. Recognize the different clinical manifestations of various infectious agents (e.g. bacteria, viruses and biotoxins).
5. Develop pharmaceutical care strategies to reduce the adverse events of both the injuries and drug therapy.